– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative technology via ...

Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks (approximately 9 ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal injections for diabetic macular edema and helps delay progression of ...

The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 1 and affects nearly 7.7 million people in the U.S. 2 ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. This piece also marks part ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies ...

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Diabetic retinopathy is the leading cause of vision loss in working-aged people in the U.S. It’s a complex disease that can lead to irreversible vision loss. Diabetes affects the retina, a fine layer ...

A report in the December issue of the Archives of Ophthalmology shows that injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of ...

February 7, 2012 — The Diabetic Retinopathy Clinical Research (DRCR) Network is a network of community- and academic-based ophthalmologists that has been conducting clinical research related to ...

Diabetic retinopathy in patients with DME is the fourth approved indication for EYLEA in the U.S. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) Safety data were ...